Antifungal treatment: Recent advances in dermatology;Tratamiento antifungico: Ultimos avances en dermatologia

Revista Iberoamericana de Micologia

Volumn 16, Issue 2, 1999, Pages 86-91

  Del Palacio, Amalia ^a   Garau, Margarita ^a   Tena, Daniel ^a   Sánchez, Gracia ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Butenafine; Cyclodextrin; Fluconazole; Itraconazole; Terbinafine; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; BUTENAFINE; FLUCONAZOLE; ITRACONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIMICROBIAL THERAPY; DERMATOMYCOSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; THRUSH; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS;

EID: 0032768318     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. del Palacio A, Cuétara MS, Roig MP, et al. Nuevas perspectives en el tratamiento de las micosis superficiales. Rev Iberoam Micol 1993; 10: 93-100.
2. del Palacio A, Cuétara MS, Amor E, et al. Ultimos avances en el tratamiento de dermatofitosis y tinea unguium. Rev Iberoam Micol 1996; 13: S2-S5.
3. Loftsson T, Olafsson JH. Cyclodextrins: new drug delivery systems in dermatology. Int J Dermatol 1998; 37:241-246.
4. Anónimo. Voriconazole, UK-109496. Drugs future 1997; 22: 326-327.
5. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole(UK-109496) a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1998; 41:841-843.
6. Gupta AK, Kohli Y, Li A, et al. In vitro susceptibility of the seven Malassezia species to vonconazole, terbinafine, ketoconazole and itraconazole 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, 1998: 455 (Abstract J 17).
7. Espinel-Ingroff A, del Palacio A, Moore MK. A comparison of the in vitro activity for the new triazole voriconazole with those of three established agents against dermatophytes and other molds. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 1998; 456 (Abstract J19a).
8. Viviani MA, de Marie S, Graybill IR, et al. New approaches to antifungal chemotherapy Med Mycol 1998; 36: 194-206.
9. Reynes J, Bazin C, Ajana F, et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human inmunodeficiency virus- infected adults with oral candidiasis. Antimicrob Agents Chemother 1997;41:2554-2558
10. Graybill JR, Vazquez J, Darovichie RO. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104: 33-39.
11. Phillips P, de Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26: 1368-1373.
12. Gupta AK, Solomon RS, Adam P. Itraconazole oral solution for the treatment of tinea capitis Br J Dermatol 1998; 139: 104-106.
13. Gupta AK, Lynde C, Lauzon GI, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and review of the literature Br J Dermatol 1998, 138: 529-532.
14. Amichai B, Grunwald MH. Adverse drug reactions of the new oral antifungal agents-terbinafine, fluconazole and itraconazole. Int J Dermatol 1998; 37: 410-415.
15. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997; 36 788-792.
16. Brennan BS, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol 1997; 36: S3-8.
17. Tschen E, Elewski B, Gorserlowsky DC, et al. Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997; 36: S9-S14.
18. Savin R, De Villez RL, Elewski B, et al. One-week therapy with twice-daily butena-fine 1% cream versus vehicle in the treatment of tinea pedis: A multicenter, double-blind trial J Am Acad Dermatol 1997, 36: S15-S19
19. Lesher JL, Babel DE, Stewart DE, et al. Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle controlled, double-blind trial J Am Acad Dermatol 1997; 36 S20-S24
20. Reyes BA, Beutner KR, Cullen SI, et al. Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. Int J Dermatol 1997; 37: 433-453.
21. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36: 754-756.
22. Summerbell RC. Epidemiology and ecology of onychomycosis. Dermatology 1997; 194 (Suppl.1): 32-36.
23. Elewski BE. Large scale epidemiological study of the causal agents of onychomycosis. mycological findings from the multicenter onychomycosis study of terbinafine. Arch Dermatol 1997;133: 1317-1318.
24. Gupta AK, Shear NH. A questionnaire study on the management of onychomycosis: a Canadian perspective. Int J Dermatol 1998; 37: 457-460.
25. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. Pharmacoeconomics 1998; 13: 1-15.
26. Shear NH, Einarson TR, Arikiau SR, et al. Pharmacoeconomic analysis of topical treatments for tinea infections, Int J Dermatol 1998; 37: 64-71.
27. Molting SK, Sanchez-Carazo J, De Boulle K, et al. Oral treatment schedules for onychomycosis: a study of patient preference. Int J Dermatol 1998; 37: 454-456.
28. Roberts DT, Evans EG. Subungueal dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998, 138: 188-203.
29. Gupta AK, Scher RK. Oral antifungal agents for onychomycosis. Lancet 1998; 351 541-542.
30. Rich P, Scher RK, Breneman D, et al. Pharmacokinetics of three doses of once weekly fluconazole (150, 300 and 450 mg) in distal subungueal onychomycosis of the toenail J Am Acad Dermatol 1998; 38: S103-S109.
31. Savin RC, Drake L, Babel D, et al. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungueal onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38 S110-S116.
32. Drake L, Babel D, Stewart DM. Once weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungueal onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38 : S87-S94.
33. Ling MR, Swinyer LJ, Taylor Jarrat M, et al. Once weekly fluconazole (450 mg) for 4, 6 or 9 months of treatment for distal subungueal onychomycosis of the toenail. J Am Acad Dermatol 1998;38 S95-S102
34. Odom RB, Aly R, Scher RK, et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 1997; 36: 231-235.
35. Havu V, Brandt H, Heikkilä H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136: 230-234.
36. Elewski BE., Scher RK, Aly R, et al Double-blind, randomized comparison of itraconazole capsules vs placebo in the treatment of toenail onychomycosis. Cutis 1997; 59. 217-220.
37. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997, 37: 740-745.
38. Tausch I, Bräutigam M, Weidinger G, et al. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. Br J Dermatol 1997; 136 737-742.
39. Heikkila H, Stubb S. Long-term results of patients with onychomycosis treated with itraconazole Acta Derm Venereol (Stockh) 1997; 77: 70-71.
40. Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toe nail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months follow-up. Acta Derm Venereol (Stockh) 1997; 77: 66-69.
41. Herranz P, García J, de Lucas R, et al. Toenail onyehomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. Br J Dermatol 1997; 137: 577-580.
42. Ellis DH, Watson AB, Marley IL, et al. Nondermatophytes in onychomycosis of the toenails. Br J Dermatol 1997; 136: 490-493.
43. De Doncker PRG, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 173-177.
44. Tosti A, Piraccini BM. Proximal subungueal onychomycosis due to Aspergillus niger. report of two cases. Br J Dermatol 1998; 139: 152-169.
45. Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br J Dermatol 1997; 136: 424-427.
46. Honeyman JF, Talarico FS, Arruda LHF, et al. Itraconazole versus terbinafine (Lamisil): Which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol 1997, 9: 215-221.
47. Degreef H, del Palacio A, Mygind S, et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Dermatol Venereol: en prensa.
48. Cuétara MS, del Palacio A, Pereiro M, et al. Prevalence of undetected tinea capitis in a school survey in Spain. Mycoses 1997; 40: 131-137.
49. Cuétara MS, del Palacio A. Prevalence of undetected tinea capitis in a prospective school survey in Madrid: emergence of new causative fungi. Br J Dermatol 1998; 138: 658-660
50. Hay RJ, Clayton YM, Desilva N, et al. Tinea capitis in South-East London. A new pattern of infection with public health implications. Br J Dermatol 1996; 135: 955-958.
51. Fuller LC, Child FC, Higgins EM. Tinea capitis in South-East London: an outbreak of Trichophyton tonsurans infections. Br J Dermatol 1997; 136 139
52. Greer DL Treatment of symptom-free carriers in management of tinea capitis. Lancet 1996; 348. 350-351.
53. Elewski B. Tinea capitis. En Elgart ML (Ed) Dermatol Clin, Philadephia, WB Saunders, 1996; 14: 23-31.
54. López-Gómez S, del Palacio A, van Cutsen J, et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: A double-blind randomized study in children. Int J Dermatol 1994; 33: 743-747
55. Elewski BE. Treatment of tinea capitis with itraconazole. Int J Dermatol 1997; 36: 537-541
56. Gupta AK, Alexis ME, Raboobee N, et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicenter study. Br J Dermatol 1997, 137: 251-254.
57. Solomon BA, Riva Collins JD, Sharma R, et al. Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 1997; 37: 274-275.
58. Krafchik B. Pelletier J. The use of oral terbinafine (Lamisil) in children. Dermatology 1997; 194: S43-S44.
59. del Palacio A, Valle A, Cuétara MS Tiñas del cuero cabelludo por Microsporum cams y su tratamiento con terbinafina (Lamisil). Med Cut Iber Lat Am 1998; 26: 49-50.
60. del Palacio A, Cuétara S, Gonzalez RUIZ A. Reservas sobre la utilization de terbinafina (Lamisil) en tiñas del cuero cabelludo por Microsporum canis. Actas Dermosifiliogr 1998; 89: 211-212.
61. del Palacio A, Valle A, Pérez-Simón M, Cuétara S. Terbinafina y tinea capitis por Microsporum canis Rev Iberoam Micol 1998; 15:58.
62. del Palacio A, Cuétara S, Valle A. Terbinafine (Lamisil) therapy for Microsporum canis scalp ringworm. Clin Exp Dermatol 1998; 23: 142-143.
63. Bruckbauer HR, Hofman H. Systemic antifungal treatment of children with terbinafine. Dermatology 1997; 195: 134-135.
64. Baudraz-Rosselet F, Monod M, Joccoud S, et al. Efficacy of terbinafine treatment of tinea capitis varies according to the dermatophyte species. Br J Dermatol 1996, 135: 1011-1012.
65. Desgarennes CP, Godoy MR, Palencia AB Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans. J Am Acad Dermatol 1996; 35: 114-116.
66. Romero Aguilera G, Cortina de la Calle P, Garrido Martín JA, et al. Eficacia y seguridad de terbinafina (Lamisil) oral en et tratamiento de tin̈as del cuero cabelludo por Microsporum canis. Actas Dermosifiliogr 1998, 89: 564-570.
67. Kullavanijaya P, Ungpakorn R, Reangchainam S. The problem in tinea capitis control in a home for mentally handicapped children. Pediatr Dermatol 1995; 1073. 95-97.
68. Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis. J Am Acad Dermatol 1997; 37: 272-273
69. Jahangir M, Hussain I, Hasan MU, et al. A doubie-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 1998; 139: 672-674.
70. Bakos L, Brito AC, Castro LCM, et al Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. Pediatr Infect Dis 1997; 16: 545-548.
71. Faergemann J, Mork NJ, Haglund A, et al. A multicenter (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol 1997; 136: 575-577.
72. Gupta AK, De Doncker P, Heremans A, et al. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks J Am Acad Dermatol 1997; 36: 789-792
73. Tausch I, Decroix J, Gwiezdzinski Z, et al Short-term Itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol 1998; 37: 128-144.